{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:32:04Z","timestamp":1762522324006,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["94-03-160-30138"],"award-info":[{"award-number":["94-03-160-30138"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00436-019-06382-y","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T07:11:13Z","timestamp":1562310673000},"page":"2669-2678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO\/IR\/75\/ER)"],"prefix":"10.1007","volume":"118","author":[{"given":"Sina","family":"Mohtasebi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Mohebali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Elikaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnaz","family":"Akhoundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas Rahimi","family":"Foroushani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aref","family":"Teimouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Yarizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"issue":"1","key":"6382_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1687-7942.192997","volume":"9","author":"SM Abaza","year":"2016","unstructured":"Abaza SM (2016) Applications of nanomedicine in parasitic diseases. Parasitol United J 9(1):1\u20136","journal-title":"Parasitol United J"},{"key":"6382_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.actatropica.2017.04.029","volume":"172","author":"M Akbari","year":"2017","unstructured":"Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86\u201390","journal-title":"Acta Trop"},{"key":"6382_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","volume":"96","author":"N Aronson","year":"2017","unstructured":"Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A (2017) Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 96:24\u201345","journal-title":"Am J Trop Med Hyg"},{"key":"6382_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11270-009-0222-6","volume":"207","author":"Z Arwidsson","year":"2010","unstructured":"Arwidsson Z, Allard B (2010) Remediation of metal-contaminated soil by organic metabolites from fungi II\u2014metal redistribution. Water Air Soil Pollut 207:5\u201318","journal-title":"Water Air Soil Pollut"},{"issue":"2","key":"6382_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/nn800596w","volume":"3","author":"P Asha Rani","year":"2008","unstructured":"Asha Rani P, Low Kah Mun G, Hande MP, Valiyaveettil S (2008) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3(2):279\u2013290","journal-title":"ACS Nano"},{"key":"6382_CR6","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.2147\/IJN.S181896","volume":"13","author":"SJ Azami","year":"2018","unstructured":"Azami SJ, Teimouri A, Keshavarz H, Amani A, Esmaeili F, Hasanpour H, Elikaee S, Salehiniya H, Shojaee S (2018) Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice. Int J Nanomedicine 13:7363\u20137374","journal-title":"Int J Nanomedicine"},{"key":"6382_CR7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s13213-011-0392-5","volume":"62","author":"K Bahrami","year":"2012","unstructured":"Bahrami K, Nazari P, Sepehrizadeh Z, Zarea B, Shahverdi AR (2012) Microbial synthesis of antimony sulfide nanoparticles and their characterization. Ann Microbiol 62:1419\u20131425","journal-title":"Ann Microbiol"},{"key":"6382_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.colsurfb.2008.09.022","volume":"68","author":"DS Balaji","year":"2009","unstructured":"Balaji DS, Basavaraja S, Deshpande R, Mahesh DB, Prabhakar BK, Venkataraman A (2009) Extracellular biosynthesis of functionalized silver nanoparticles by strains of Cladosporium cladosporioides fungus. Colloids Surf B Biointerfaces 68:88\u201392","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"6382_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jtemb.2012.11.002","volume":"27","author":"N Beheshti","year":"2013","unstructured":"Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F, Dalimi A, Shahverdi AR (2013) Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies. J Trace Elem Med Bio 27(3):203\u2013207","journal-title":"J Trace Elem Med Bio"},{"key":"6382_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/clind\/24.4.684","volume":"24","author":"JD Berman","year":"1997","unstructured":"Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684\u2013703","journal-title":"Clin Infect Dis"},{"key":"6382_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/smll.200500180","volume":"2","author":"A Bharde","year":"2006","unstructured":"Bharde A, Rautaray D, Bansal V, Ahmad A, Sarkar I, Yusuf SM, Sanyal M, Sastry M (2006) Extracellular biosynthesis of magnetite using fungi. Small 2:135\u2013141","journal-title":"Small"},{"key":"6382_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111\u2013126","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"6382_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/00003495-199856060-00005","volume":"56","author":"RN Davidson","year":"1998","unstructured":"Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drugs 56(6):1009\u20131018","journal-title":"Drugs"},{"key":"6382_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/138161209787002870","volume":"15","author":"P Debbage","year":"2009","unstructured":"Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15:153\u2013172","journal-title":"Curr Pharm Des"},{"issue":"1","key":"6382_CR15","first-page":"6","volume":"9","author":"M Delavari","year":"2014","unstructured":"Delavari M, Dalimi A, Ghaffarifar F, Sadraei J (2014) In vitro study on cytotoxic effects of ZnO nanoparticles on promastigote and amastigote forms of Leishmania major (MRHO\/IR\/75\/ER). Iran J Parasitol 9(1):6\u201313","journal-title":"Iran J Parasitol"},{"issue":"10","key":"6382_CR16","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","volume":"17","author":"M den Boer","year":"2011","unstructured":"den Boer M, Argaw D, Jannin J, Alvar J (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect 17(10):1471\u20131477","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"6382_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","volume":"27","author":"P Desjeux","year":"2004","unstructured":"Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27(5):305\u2013318","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"6382_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cellimm.2018.07.002","volume":"332","author":"S Elikaee","year":"2018","unstructured":"Elikaee S, Mohebali M, Rezaei S, Eslami H, Khamesipour A, Keshavarz H, Eshraghian MR (2018) Development of a new live attenuated Leishmania major p27 gene knockout: safety and immunogenicity evaluation in BALB\/c mice. Cell Immunol 332:24\u201331","journal-title":"Cell Immunol"},{"issue":"5","key":"6382_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15051037","volume":"15","author":"M El-Khadragy","year":"2018","unstructured":"El-Khadragy M, Alolayan EM, Metwally DM, El-Din MFS, Alobud SS, Alsultan NI, Alsaif SS, Awad MA, Abdel Moneim AE (2018) Clinical efficacy associated with enhanced antioxidant enzyme activities of silver nanoparticles biosynthesized using Moringa oleifera leaf extract, against cutaneous leishmaniasis in a murine model of Leishmania major. Int J Environ Res Public Health 15(5):E1037","journal-title":"Int J Environ Res Public Health"},{"key":"6382_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/AAC.43.2.278","volume":"43","author":"M Ephros","year":"1999","unstructured":"Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D (1999) Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43:278\u2013282","journal-title":"Antimicrob Agents Chemother"},{"key":"6382_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.microc.2010.05.010","volume":"97","author":"R Feng","year":"2011","unstructured":"Feng R, Wei C, Tu S, Tang S, Wu F (2011) Simultaneous hyperaccumulation of arsenic and antimony in cretan brake fern: evidence of plant uptake and subcellular distributions. Microchem J 97:38\u201343","journal-title":"Microchem J"},{"key":"6382_CR22","volume-title":"Clinical epidemiology: the essentials","author":"RH Fletcher","year":"1996","unstructured":"Fletcher RH, Fletcher SW, Wagner EH (1996) Clinical epidemiology: the essentials, 3rd edn. Williams and Wilkins, Baltimore","edition":"3"},{"key":"6382_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","volume":"12","author":"M Ghorbani","year":"2018","unstructured":"Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12:25\u201340","journal-title":"Drug Des Devel Ther"},{"key":"6382_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1128\/CMR.6.3.230","volume":"6","author":"GJ Grimaldi","year":"1993","unstructured":"Grimaldi GJ, Tesh RB (1993) Leishmaniases of the New World: current concepts and implications for future research. Clin Microbial Rev 6:230\u2013250","journal-title":"Clin Microbial Rev"},{"issue":"1","key":"6382_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1039\/C5CS00674K","volume":"45","author":"V Guti\u00e9rrez","year":"2016","unstructured":"Guti\u00e9rrez V, Seabra AB, Reguera RM, Khandare J, Calder\u00f3n M (2016) New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev 45(1):152\u2013168","journal-title":"Chem Soc Rev"},{"key":"6382_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.saa.2006.09.028","volume":"67","author":"MI Husseiny","year":"2007","unstructured":"Husseiny MI, Abd El-Aziz M, Badr Y, Mahmoud MA (2007) Biosynthesis of gold nanoparticles using Pseudomonas aeruginosa. Spectrochim Acta Part A 67:1003\u20131006","journal-title":"Spectrochim Acta Part A"},{"key":"6382_CR27","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.tiv.2013.06.002","volume":"27","author":"A Jebali","year":"2013","unstructured":"Jebali A, Kazemi B (2013) Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis. Toxicol in Vitro 27:1896\u20131904","journal-title":"Toxicol in Vitro"},{"key":"6382_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.colsurfb.2009.02.007","volume":"71","author":"AK Jha","year":"2009","unstructured":"Jha AK, Prasad K, Kulkarni AR (2009a) Synthesis of TiO2 nanoparticles using microorganisms. Colloids Surf B Biointerfaces 71:226\u2013229","journal-title":"Colloids Surf B Biointerfaces"},{"key":"6382_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.bej.2008.10.016","volume":"43","author":"AK Jha","year":"2009","unstructured":"Jha AK, Prasad K, Prasad K (2009b) A green low-cost biosynthesis of Sb2O3 nanoparticles. Biochem Eng J 43:303\u2013306","journal-title":"Biochem Eng J"},{"key":"6382_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.colsurfb.2009.01.016","volume":"71","author":"K Kathiresan","year":"2009","unstructured":"Kathiresan K, Manivannan S, Nabeel AM, Dhivya B (2009) Studies on silver nanoparticles synthesized by a marine fungus Penicillum fellutanum isolated from coastal mangrove sediment. Colloids Surf B Biointerfaces 71:133\u2013137","journal-title":"Colloids Surf B Biointerfaces"},{"key":"6382_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1049\/iet-nbt.2014.0062","volume":"9","author":"I Khan","year":"2015","unstructured":"Khan I, Khan M, Umar MN, Oh DH (2015) Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnol 9:396\u2013400","journal-title":"IET Nanobiotechnol"},{"key":"6382_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00253-005-0179-3","volume":"69","author":"D Mandal","year":"2006","unstructured":"Mandal D, Bolander ME, Mukhopadhyay D, Sarkar G, Mukherjee P (2006) The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol 69:485\u2013492","journal-title":"Appl Microbiol Biotechnol"},{"issue":"4","key":"6382_CR33","first-page":"285","volume":"17","author":"M Mohebali","year":"2009","unstructured":"Mohebali M, Rezayat M, Gilani K, Sarkar S, Akhoundi B, Esmaeili J et al (2009) Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO\/IR\/75\/ER): an in vitro and in vivo study. Daru 17(4):285\u2013289","journal-title":"Daru"},{"key":"6382_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0014-4894(85)90067-0","volume":"59","author":"JC Mottram","year":"1985","unstructured":"Mottram JC, Coombs GH (1985) Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp Parasitol 59:151\u2013160","journal-title":"Exp Parasitol"},{"key":"6382_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/AEM.70.1.52-60.2004","volume":"70","author":"RS Oremland","year":"2004","unstructured":"Oremland RS, Herbel MJ, Blum JS, Langley S, Beveridge TJ, Ajayan PM, Sutto T, Ellis AV, Curran S (2004) Structural and spectral features of selenium nanospheres produced by Se-respiring bacteria. Appl Environ Microbiol 70:52\u201360","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"6382_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/157341312801784221","volume":"8","author":"P Prabhu","year":"2012","unstructured":"Prabhu P, Patravale V, Joshi M (2012) Nanocarriers for effective topical delivery of anti-infectives. Curr Nanosci 8(4):491\u2013503","journal-title":"Curr Nanosci"},{"key":"6382_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-18312-6","volume-title":"In metal nanoparticles In Microbiology","author":"M Rai","year":"2011","unstructured":"Rai M, Gade A, Yadav A (2011) Biogenic nanoparticles: an introduction to what they, how they are synthesized and their applications. In: Rai MK, Duran N (eds) In metal nanoparticles In Microbiology. Springer-Verlag, Berlin Heidelberg, Germany, pp 1\u201316"},{"key":"6382_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","volume":"7","author":"R Reithinger","year":"2007","unstructured":"Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581\u2013596","journal-title":"Lancet Infect Dis"},{"key":"6382_CR39","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1128\/AAC.39.6.1234","volume":"39","author":"WL Roberts","year":"1995","unstructured":"Roberts WL, Berman JD, Rainey PM (1995) In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 39:1234\u20131239","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6382_CR40","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1128\/AAC.42.5.1076","volume":"42","author":"WL Roberts","year":"1998","unstructured":"Roberts WL, Mcmurray WJ, Rainey PM (1998) Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob Agents Chemother 42(5):1076\u20131082","journal-title":"Antimicrob Agents Chemother"},{"key":"6382_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4028\/www.scientific.net\/JNanoR.20.89","volume":"20","author":"B Rossi-Bergmann","year":"2012","unstructured":"Rossi-Bergmann B, Pacienza-Lima W, Marcato PD, De Conti R, Dur\u00e1n N (2012) Therapeutic potential of biogenic silver nanoparticles in murine cutaneous leishmaniasis. J Nano Res 20:89\u201397","journal-title":"J Nano Res"},{"key":"6382_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/AAC.41.5.972","volume":"41","author":"D Sereno","year":"1997","unstructured":"Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41:972\u2013976","journal-title":"Antimicrob Agents Chemother"},{"key":"6382_CR43","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1128\/AAC.42.12.3097","volume":"42","author":"D Sereno","year":"1998","unstructured":"Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL (1998) Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 42:3097\u20133102","journal-title":"Antimicrob Agents Chemother"},{"key":"6382_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1042\/BA20100042","volume":"56","author":"M Shakibaei","year":"2010","unstructured":"Shakibaei M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR (2010) Biosynthesis and recovery of selenium nanoparticles and the effects onmatrixmetalloproteinase-2 expression. Biotechnol Appl Biochem 56:7\u201315","journal-title":"Biotechnol Appl Biochem"},{"key":"6382_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/756568","volume":"2012","author":"S Soflaei","year":"2012","unstructured":"Soflaei S, Dalimi A, Ghaffarifar F, Shakibaie M, Shahverdi AR, Shafiepour M (2012) In vitro antiparasitic and apoptotic effects of antimony sulfide nanoparticles on Leishmania infantum. J Parasitol Res 2012:756568","journal-title":"J Parasitol Res"},{"key":"6382_CR46","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/IJN.S158736","volume":"13","author":"A Teimouri","year":"2018","unstructured":"Teimouri A, Azami SJ, Keshavarz H et al (2018) Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomedicine 13:1341\u20131351","journal-title":"Int J Nanomedicine"},{"key":"6382_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nano.2009.07.002","volume":"6","author":"KN Thakkar","year":"2010","unstructured":"Thakkar KN, Mhatre SS, Parikh RY (2010) Biological synthesis of metallic nanoparticles. Nanomed Nanotechnol Biol Med 6:257\u2013262","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"6382_CR48","first-page":"13","volume":"1","author":"N Torabi","year":"2011","unstructured":"Torabi N, Mohebali M, Shahverdi AR, Rezayat SM, Edrissian GH, Esmaeili J et al (2011) Nanogold for the treatment of zoonotic cutaneous leishmaniasis caused by Leishmania major (MRHO\/IR\/75\/ER): an animal trial with methanol extract of Eucalyptus camaldulensis. JPHS 1:13\u201316","journal-title":"JPHS"},{"key":"6382_CR49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biotechadv.2009.08.001","volume":"27","author":"R Vaidyanathan","year":"2009","unstructured":"Vaidyanathan R, Kalishwaralal K, Gopalram S, Gurunathan S (2009) Nanosilver\u2014the burgeoning therapeutic molecule and its green synthesis. Biotechnol Adv 27:924\u2013937","journal-title":"Biotechnol Adv"},{"issue":"5","key":"6382_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1046\/j.1365-3156.2000.00555.x","volume":"5","author":"H Veeken","year":"2000","unstructured":"Veeken H, Ritmeijer K, Seaman J, Davidson R (2000) A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Tropical Med Int Health 5(5):312\u2013317","journal-title":"Tropical Med Int Health"},{"key":"6382_CR51","first-page":"765","volume":"6","author":"JJ Wang","year":"2011","unstructured":"Wang JJ, Zeng ZW, Xiao RZ et al (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 6:765\u2013774","journal-title":"Int J Nanomedicine"},{"key":"6382_CR52","unstructured":"World Health Organization (2014) Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region"},{"issue":"6","key":"6382_CR53","first-page":"587","volume":"74","author":"M Yaghoobi-Ershadi","year":"1996","unstructured":"Yaghoobi-Ershadi M, Javadian E (1996) Epidemiological study of reservoir hosts in an endemic area of zoonotic cutaneous leishmaniasis in Iran. Bull World Health Organ 74(6):587","journal-title":"Bull World Health Organ"},{"issue":"9217","key":"6382_CR54","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(00)02270-4","volume":"355","author":"E Zuccato","year":"2000","unstructured":"Zuccato E, Calamari D, Natangelo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. Lancet 355(9217):1789\u20131790","journal-title":"Lancet"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-019-06382-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00436-019-06382-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-019-06382-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:20:30Z","timestamp":1593818430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00436-019-06382-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["6382"],"URL":"https:\/\/doi.org\/10.1007\/s00436-019-06382-y","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"type":"print","value":"0932-0113"},{"type":"electronic","value":"1432-1955"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal care and experiments were carried out according to the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and approved by the Ethical Committee of Tehran University of Medical Sciences, Tehran, Iran. The study was approved by the Ethical Committee of Tehran University of Medical Sciences (Approval No. 94-03-160-30138).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (no individual persons data)","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}